*2 deaths (acute myocardial infarction, n=1; Burkitt's lymphoma, n=1) in GEMINI-2 study; both were in the DTG + 3TC group and were considered unrelated to the study drug regimen. 1
Most common adverse events for TIVICAY + Lamivudine (pooled) (data from the GEMINI-1 and -2 studies): 1
Adverse events occurring in ≥5% of participants in either arm 1
Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.